GMRx-4 IR
AssetSmall moleculeAlso GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin, GMRx-4 IR polypill
Polypill containing an SGLT2 inhibitor, DPP-4 inhibitor, and biguanide for glycemic control.
- Stage
- Stage not known
- Modality
- Small molecule
- Target
- AMPK signalling
- Indications
- 0
- Trials
- 1,682
- Developers
- 1
Indications
0- Targets and what it contains7
- Owner and partners1
- Trials1,682
- Evidence for its targets7
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 3 sources